Mitral Regurgitation News and Research

RSS

European Dynamic Annuloplasty Activation study completes patient enrollment

MiCardia (MiCardia Corporation, Irvine, California) today announced the completion of enrollment in its European “DYANA” (Dynamic Annuloplasty Activation) study, designed to support submission for CE mark of the firm’s Dynaplasty technology in Europe.

9 Sep 2009

Patients suffering from functional and degenerative mitral regurgitation treated using the MitraClip system

Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, today announced treatment of the first group of patients with the MitraClip(R) system at the Karolinska University Hospital in Solna, Stockholm, Sweden.

24 Aug 2009

New device for patients too sick for open-heart surgery

An innovative device that acts like a belt to reshape an enlarged, leaky heart valve is providing a minimally invasive treatment option for patients who are too sick for open-heart surgery.

7 May 2009

Percutaneous mitral valve repair

The scope of percutaneous cardiac therapy has expanded from percutaneous coronary and peripheral intervention to percutaneous valve intervention, first used in the mid eighties.

1 Sep 2008

Catheter repair of mitral valve improves heart size, symptoms

A catheter-mounted device that acts like a clothespin to clip together the flaps of a leaky heart valve is not only reducing the abnormal backflow of blood from the left ventricle to the left atrium, it is helping to shrink the enlarged, overworked heart and relieving symptoms of fluid overload - all without open-chest surgery.

2 Apr 2008

Exercise testing to predict mitral regurgitation

In as many as one in five people over age 55, when the heart contracts to send blood around the body, some degree of backward leakage occurs across the mitral valve, a condition known as mitral regurgitation (MR).

12 Dec 2007

Exercise testing may help predict seriousness of mitral regurgitation

12 Dec 2007

Myocor receives trial approval for percutaneously implanted iCoapsys system

Myocor, Inc. announced that the U.S. Food and Drug Administration has granted conditional approval of the Valvular and Ventricular Improvement Via iCoapsys Delivery (VIVID) feasibility study.

5 Dec 2007

Review of percutaneous valve therapy

Researchers at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation (CRF), will present new studies evaluating a rapidly advancing field within interventional cardiology: percutaneous procedures to repair and replace defective heart valves.

24 Oct 2007

Cardiosolutions raises $7 million for minimally invasive system for repair of regurgitant mitral valves

Cardiosolutions, Inc. has closed a $7 million Series A Convertible Preferred Stock financing led by BioVentures Investors, the company announced.

25 Sep 2007

Imaging and percutaneous valve therapy

The scope of percutaneous cardiac therapy has expanded from percutaneous coronary and peripheral intervention to percutaneous valve intervention, first used in the mid- eighties. Today mitral regurgitation represents the second most important native valve disease in Europe (30%) as shown by the Euro Heart Survey.

3 Sep 2007

First European guidelines on the management of valvular heart disease

Today valve disease still represents an important health problem; valve patients are getting older and older with more and more comorbities, which contribute to increased operative risk and render the decision-making process more difficult.

3 Sep 2007

Advances in clinical cardiology

Three studies being presented at the American College of Cardiology's Innovation in Intervention: i2 Summit 2007 in New Orleans, La., highlight the breadth of research propelling advances in clinical cardiology.

3 Apr 2007

New technology offers alternative to open heart surgery

A new method of treating mitral regurgitation (MR), the leaking of blood through the mitral valve into the heart chamber, provides a less-invasive alternative to open heart surgery.

19 Nov 2006

Beta-blockers can benefit patients with certain serious heart problems such as diastolic heart failure

Beta-blockers, medications that block the action of certain hormones on the heart, can benefit patients with certain serious heart problems such as diastolic heart failure, according to cardiologists at the Keck School of Medicine of the University of Southern California and Loma Linda University Medical Center.

7 Mar 2005

Surgery gives normal life expectancy to patients with severe mitral regurgitation

"We know from previous studies that patients with symptomatic mitral regurgitation are at increased risk of death, but for those without symptoms the picture has been murkier," says Maurice Enriquez-Sarano, M.D., the Mayo Clinic cardiologist who led the study. "In this study we followed a large population of asymptomatic patients prospectively to identify keys to improved long-term outcomes, and to determine when patients should consider surgery."

2 Mar 2005

Basic biochemical composition of heart valves in patients with congestive heart failure are markedly different than those with healthy hearts

Surprising new findings in the Journal of the American College of Cardiology show that the basic biochemical composition of heart valves in patients with congestive heart failure are markedly different than those with healthy hearts, a finding that may explain the mixed success of surgery to repair valve dysfunction in these patients.

25 Jan 2005